预测中轴型脊柱关节炎患者对抗TNFα治疗的反应:BSRBR-AS研究结果
BSRBR-AS前瞻性队列研究中,335例首次启用抗TNFα治疗的中轴型脊柱关节炎患者,中位随访14周,按不同标准应答率为33%至52%。不良社会经济因素、教育年限少、未全职工作、合并症及心理健康差与缺乏应答相关,模型对无应答的阴性预测值达77%。
要点
- 抗TNFα治疗中轴型脊柱关节炎的应答率因评估标准而异,范围为33%至52%。
- 教育年限少、未全职工作、合并症及心理健康差与治疗无应答相关。
- 预测模型对无应答的阴性预测值为77%,有助于识别不太可能获益的患者。
核心结论
- 部分预测无应答的因素(如心理健康)可干预,但许多社会经济因素在临床中不可改变,不过可识别不太可能仅从生物制剂治疗中获益的患者。
研究设计与样本
- BSRBR-AS为前瞻性队列研究,纳入招募时未使用过生物制剂的中轴型脊柱关节炎患者,其中335例启动首剂抗TNFα治疗并随访,中位随访14周(四分位距12-17周)。
主要发现
- 根据所用标准不同,应答率在33%至52%之间。
- 不良社会经济因素、教育年限少及未全职工作预测所有结局指标应答可能性更低。
- 合并症和心理健康差分别作为临床和患者报告因素与缺乏应答相关。
- 预测模型(尤其使用ASDAS的模型)对无应答的阴性预测值为77%。
关键数值与推荐
- 结局评估采用ASAS20、ASAS40、ASDAS下降及达到中度/不活动ASDAS疾病状态。
- 使用ASDAS的模型对无应答的阴性预测值为77%。
临床怎么用
- 临床中可识别教育年限少、未全职工作、合并症及心理健康差的患者,这些患者不太可能仅从抗TNFα治疗中获益,应优先关注如何让这些患者获得其他人从治疗中获得的益处。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: While many axSpA patients, eligible to receive anti-TNFα therapy, derive benefit when prescribed them, some patients do not. The current study aims to identify modifiable targets to improve outcome as well as non-modifiable targets that identify groups less likely to derive benefit. METHODS: The BSRBR-AS is a prospective cohort study of axSpA patients who, at recruitment, were naïve to biologic therapy. Those in the 'biologic' sub-cohort commenced their first anti-TNFα therapy at recruitment or during follow-up. Prior to commencement, information was collected on socio-economic, clinical and patient-reported factors. Outcome was assessed according to ASAS20, ASAS40, ASDAS reduction and achieving a moderate/inactive ASDAS disease state. RESULTS: 335 participants commenced their first anti-TNFα therapy and were followed up at a median of 14 (inter-quartile range 12-17) weeks. Response varied between 33% and 52% according to criteria used. Adverse socio-economic factors, fewer years in education predicted lower likelihood of response across outcome measures as did not working full-time. Co-morbidities and poor mental health were clinical and patient-reported factors, respectively, associated with lack of response. The models, particularly those using ASDAS, were good at predicting those who did not respond (negative predictive value (NPV) 77%). CONCLUSION: Some factors predicting non-response (such as mental health) are modifiable but many (such as social/economic factors) are not modifiable in clinic. They do, however, identify patients who are unlikely to benefit from biologic therapy alone. Priority should focus on how these patients receive the benefits that many derive from such therapies.
引用
- Macfarlane GJ, Pathan E, Jones GT, et al. Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology (Oxford). 2020. PMID: 31990352. doi:10.1093/rheumatology/kez657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。